Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Coherus Oncology (CHRS) Long-Term Debt Repayments (2022 - 2024)

Coherus Oncology's Long-Term Debt Repayments history spans 2 years, with the latest figure at $85.4 million for Q2 2024.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $85.4 million in Q2 2024 year-over-year; TTM through Sep 2025 was $85.4 million, a 24.19% decrease, with the full-year FY2025 number at $233.2 million, down 10.45% from a year prior.
Long-Term Debt Repayments hit $85.4 million in Q2 2024 for Coherus Oncology, up from $27.2 million in the prior quarter.
Over the last five years, Long-Term Debt Repayments for CHRS hit a ceiling of $111.1 million in Q1 2022 and a floor of -$29.4 million in Q2 2022.